COUPANG, INC.22266T109US22266T109706/11/2026To consider a non-binding vote to approve the compensation of Coupang, Inc.'s named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER14129460FOR1412946FOR LYELL IMMUNOPHARMA, INC.55083R203US55083R203106/10/2026Approval, on a non-binding advisory basis, of the compensation of the company's named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER00 META PLATFORMS, INC.30303M102US30303M102705/27/2026A shareholder proposal regarding annual vote regarding executive pay.SECTION 14A SAY-ON-PAY VOTESSECURITY HOLDER333000AGAINST33300FOR NEUMORA THERAPEUTICS, INC.640979100US640979100005/27/2026Advisory vote on the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER00 NEUMORA THERAPEUTICS, INC.640979100US640979100005/27/2026Advisory vote on the frequency of future advisory votes on the compensation of our named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER00 RECURSION PHARMACEUTICALS, INC.75629V104US75629V104406/17/2026Advisory vote to approve executive compensation as disclosed in the 2026 Proxy Statement.SECTION 14A SAY-ON-PAY VOTESISSUER84517580FOR8451758FOR RESTAURANT BRANDS INTERNATIONAL INC.76131D103CA76131D103306/03/2026Approval, on a non-binding advisory basis, of the compensation paid to named executive officers.SECTION 14A SAY-ON-PAY VOTESISSUER3862030FOR386203FOR REVOLUTION MEDICINES, INC.76155X100US76155X100006/18/2026To approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers as disclosed in the Proxy Statement pursuant to the compensation disclosure rules of the Securities and Exchange Commission ("Say-on-Pay").SECTION 14A SAY-ON-PAY VOTESISSUER5085690FOR508569FOR SEADRILL LIMITEDG7997W102BMG7997W102906/03/2026To conduct an advisory vote to approve the compensation of our named executive officers for 2025.SECTION 14A SAY-ON-PAY VOTESISSUER00